Aurobindo Pharma Limited (AUROPHARMA) Fair Value & Analysis
Healthcare · IN · Market cap ₹891B (≈ $9.4B) · ISIN INE406A01037
What is Aurobindo Pharma Limited really worth?
A solid business, trading 31% below our fair value of ₹2,412.
Strengths
Risks
Fair value as of: Aug 19, 2026
From 26 valuation models · updated 17 days ago
Fair value updated Aug 19, 2026, revised from ₹1,340 to ₹2,412 (+80.0%) since Aug 13, 2026. Share price +2.5% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- Solid quality (57/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (₹1,582 to ₹3,015) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 19, 2026.
How to read this chart
60‑month range ₹397.96 – ₹1,717 · fair‑value band ₹1,582 – ₹3,015 · the ₹1,653 price screens below the ₹2,412 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 19, 2026.
Analysis
Aurobindo Pharma Limited (AUROPHARMA) currently trades at ₹1,653, while our model-based Fair Value estimate is ₹2,412, implying the stock looks roughly 31.5% undervalued today. The Quality Score stands at 57/100 (solid quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of ₹1,566 per share, and 6 of the 26 models we run sit above the ₹1,653 price. Bear case: the Asset-Based group reads lowest at ₹441.22, and 20 of the 26 models stay below the price. Evidence for this calculation is medium.
Over the trailing twelve months, Aurobindo Pharma Limited generated revenue of ₹337B at a net margin of 10.4%. Revenue grew 5.6% year over year. It earns a return on equity of 9.9%. The balance sheet holds a net cash position of ₹18.0B. Fundamentals as of Aug 19, 2026
Our scenario range runs from ₹1,582 (bear case) to ₹3,015 (bull case); at ₹1,653, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 63% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at 46%, AUROPHARMA screens cheaper than that median.
Fair Value models
This estimate rests on fiscal year 2026 figures, and about 5 months have passed since. In that time the company retained roughly ₹26.10 per share, which is 1.1 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 26 models by family
Widest divergence: DCF Models (₹1,566) versus Dividend Discount (₹69.48). Highest evidence: FCF DCF (77).
Notify me when AUROPHARMA reaches fair value
Put AUROPHARMA on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 58 · Market factors (momentum, volatility) 87
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables.
Full company description
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Aurobindo Pharma Limited reported revenue of ₹337B in FY2026 versus ₹235B in FY2022, a compound +9.4%/yr. Reported net income was ₹35.0B in FY2026, compounding +7.3%/yr from FY2022.
of which total revenue +9.7 % · buybacks/dilution +0.0 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
Watch AUROPHARMA: get an alert when its fair value changes →
Earlier news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Aurobindo Pharma (NSEI:AUROPHARMA) Stock Sees Modest Fair Value Lift On Revised Assumptions
- India's Aurobindo Pharma says director arrested by Enforcement Directorate
Peer Group
Drug Manufacturers - Specialty & Generic · 608 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €140.25 | €106.48 | −24% |
| Takeda Pharmaceutical Company TAK | $18.03 | $11.11 | −38% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | −52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | −49% |
| Galderma Group GALD | CHF 178.55 | CHF 55.07 | −69% |
| Haleon plc HLN | $10.11 | $7.64 | −24% |
| Teva Pharmaceutical Industries Limited TEVA | $36.05 | $15.33 | −57% |
| Sandoz Group SDZ | CHF 70.66 | CHF 39.21 | −45% |
| Zoetis Inc ZTS | $77.10 | $104.88 | +36% |
| Hansoh Pharmaceutical Group 3692 | HK$35.12 | HK$16.18 | −54% |
Compare Aurobindo Pharma Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Aurobindo Pharma Limited (AUROPHARMA) overvalued or undervalued?
What is the fair value of AUROPHARMA?
What is the quality score of AUROPHARMA?
What is the revenue of Aurobindo Pharma Limited (AUROPHARMA)?
What is the net profit margin of AUROPHARMA?
Does Aurobindo Pharma Limited pay a dividend?
Watch Aurobindo Pharma Limited in the live analysis
One click puts Aurobindo Pharma Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.